Cargando…

FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?

Detalles Bibliográficos
Autores principales:	Lamarca, Angela, Foster, Lucy, Valle, Juan W, Satyadas, Thomas, Siriwardena, Ajith
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7597489/ https://www.ncbi.nlm.nih.gov/pubmed/33122352 http://dx.doi.org/10.1136/esmoopen-2019-000633

Ejemplares similares

FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study
por: Vienot, Angélique, et al.
Publicado: (2020)

FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma
por: Yoo, Changhoon, et al.
Publicado: (2020)

A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma
por: Hosein, Peter J, et al.
Publicado: (2012)

Neoadjuvant chemotherapy in locally advanced duodenal adenocarcinoma
por: Velandia, Carlos, et al.
Publicado: (2018)

Are We Missing Out on Something?
por: Kapoor, Astha Koolwal, et al.
Publicado: (2018)

Work-Up and Outcome of Hepatic Resection for Peri-Hilar Cholangiocarcinoma (PH-CCA) without Staging Laparoscopy
por: Jegatheeswaran, Santhalingam, et al.
Publicado: (2022)

FOLFIRINOX relative dose intensity and disease control in advanced pancreatic adenocarcinoma
por: Vary, Antonin, et al.
Publicado: (2021)

Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as Adjuvant Chemotherapy
por: Mortier, Victor, et al.
Publicado: (2022)

Use of Pharmacologic Agents for Modulation of Ischaemia-Reperfusion Injury after Hepatectomy: A Questionnaire Study of the LiverMetSurvey International Registry of Hepatic Surgery Units
por: Jegatheeswaran, Santhalingam, et al.
Publicado: (2014)

Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma
por: Gilabert, Marine, et al.
Publicado: (2017)

Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinoma
por: Ulusakarya, Ayhan, et al.
Publicado: (2019)

An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma
por: Péron, Julien, et al.
Publicado: (2016)

FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study
por: Suker, Mustafa, et al.
Publicado: (2018)

Efficacy and Toxicity of Folfoxiri for Patients with Metastatic Colorectal Cancer
por: Huy, Trinh Le, et al.
Publicado: (2019)

Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Observational Study
por: Servetto, Alberto, et al.
Publicado: (2021)

Quality of life of locally advanced pancreatic cancer patients after FOLFIRINOX treatment
por: van der Sijde, Fleur, et al.
Publicado: (2021)

Meta-analysis of FOLFIRINOX-based neoadjuvant therapy for locally advanced pancreatic cancer
por: Chen, Zhiliang, et al.
Publicado: (2021)

FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium
por: Janssen, Quisette P, et al.
Publicado: (2022)

Thoracic surgical management of colorectal lung metastases: a questionnaire survey of members of the Society for Cardiothoracic Surgery in great Britain and Ireland
por: Jegatheeswaran, S, et al.
Publicado: (2013)

FOLFOXIRI Resistance Induction and Characterization in Human Colorectal Cancer Cells
por: Ramzy, George M., et al.
Publicado: (2022)

FOLFIRINOX in Locally Advanced and Metastatic Pancreatic Cancer: A Single Centre Cohort Study
por: Rombouts, SJ, et al.
Publicado: (2016)

Clinical outcomes of FOLFIRINOX in locally advanced pancreatic cancer: A single center experience
por: Lee, Jongchan, et al.
Publicado: (2018)

Induction FOLFIRINOX followed by stereotactic body radiation therapy in locally advanced pancreatic cancer
por: Jung, Jae Hyup, et al.
Publicado: (2022)

Clinical Value of Pharmacogenomic Testing in a Patient Receiving FOLFIRINOX for Pancreatic Adenocarcinoma
por: Velez-Velez, Lisa M., et al.
Publicado: (2018)

Using Exome Sequencing to Improve Prediction of FOLFIRINOX First Efficacy for Pancreatic Adenocarcinoma
por: Lecuelle, Julie, et al.
Publicado: (2021)

Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis
por: Choi, Jin G., et al.
Publicado: (2018)

Clinical Impact of the Administration of FOLFIRINOX Beyond Six Months in Advanced Pancreatic Adenocarcinoma: A Cohort Study
por: Nitipir, Cornelia, et al.
Publicado: (2021)

Are We Missing Out on Critically Appraised Topics in Ophthalmology Journals?
por: Hassanpour, Kiana, et al.
Publicado: (2021)

FOLFOXIRI plus bevacizumab as standard of care for first-line treatment in patients with advanced colon cancer
por: Cervantes, A., et al.
Publicado: (2023)

First case report of neoadjuvant gemcitabine and S-1 for locally advanced unresectable duodenal adenocarcinoma
por: Kimura, Jiro, et al.
Publicado: (2022)

Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX
por: Choi, Young Hoon, et al.
Publicado: (2021)

Results of a single-arm pilot study of (32)P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy
por: Ross, P.J., et al.
Publicado: (2021)

Neoadjuvant FOLFIRINOX Application in Borderline Resectable Pancreatic Adenocarcinoma: A Retrospective Cohort Study
por: Paniccia, Alessandro, et al.
Publicado: (2014)

Maintenance Therapy with FOLFIRI after FOLFIRINOX for Advanced Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Center Analysis
por: Franck, Caspar, et al.
Publicado: (2019)

Liver resection following FOLFOXIRI plus bevacizumab: a detailed pathological review
por: Walter, H, et al.
Publicado: (2013)

Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors
por: Sunakawa, Yu, et al.
Publicado: (2018)

Case report: potential treatment of metastatic amphicrine carcinoma of the rectum with FOLFOXIRI chemotherapy
por: Tamura, Nobumasa, et al.
Publicado: (2020)

FOLFOXIRI in Pregnant Women with Colorectal Cancer: A Case Report and Review of the Literature
por: Kozai, Landon, et al.
Publicado: (2022)

Phasing out the pre-transplant cytotoxicity crossmatch: Are we missing something?
por: Abud, Jamile, et al.
Publicado: (2021)

Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer
por: Stein, Stacey M, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_g743v8hq36indbdno2dsr8jq7i